The AIM-HI Accelerator Fund (AIM-HI) just announced 6 Semi-Finalists for the 2022 AIM-HI Women’s Venture…
The AIM-HI Accelerator Fund is proud to support our Portfolio Company, SciTech Development, to present at the Virtual 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference. This Virtual Event will take place on January 11-12, 2021, co-hosted by our partner organization, China Pharmaceutical Innovation and Research Development Association (PhIRDA).
Register FOR FREE to attend: https://zhibo.m-events.cn/live/watch/general?id=o92y0v6m
This Forum will focus on the new dynamics and trends of global investment and financing, select high-quality innovative companies to showcase their innovations and achievements, promote international cooperation in the field of pharmaceutical innovation and jointly build new pattern of the pharmaceutical industry in the post-pandemic era.
SciTech Development is a clinical-stage, pharmaceutical company that has developed a patented, proprietary drug delivery “platform” that enables the optimization of intravenous delivery and cellular penetration of water-insoluble drugs. ST-001 is the first drug asset utilizing this transformative delivery approach. Fenretinide has been shown in 3000 patients, to be a safe/effective anticancer therapy. Fenretinide demonstrated antiviral and immunomodulatory impact on three virus types. SciTech has IND approval for an orphan-drug, accelerated T-cell lymphoma clinical trial, plus FDA guidance for an IND targeting a COVID-19 pathway. Data suggest ST-001 will solve absorption/bioavailability challenges, reduce side effects, allow for high potency IV dosing, thereby improving outcomes.